- Home
- ESSA vs CRVS Comparison
ESSA vs CRVS Comparison
Compare ESSA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESSA
- CRVS
- Stock Information
- Founded
- ESSA 1916
- CRVS 2014
- Country
- ESSA United States
- CRVS United States
- Employees
- ESSA N/A
- CRVS N/A
- Industry
- ESSA Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ESSA Finance
- CRVS Health Care
- Exchange
- ESSA Nasdaq
- CRVS Nasdaq
- Market Cap
- ESSA N/A
- CRVS 257.0M
- IPO Year
- ESSA N/A
- CRVS 2016
- Fundamental
- Price
- ESSA $18.85
- CRVS $3.18
- Analyst Decision
- ESSA
- CRVS Strong Buy
- Analyst Count
- ESSA 0
- CRVS 5
- Target Price
- ESSA N/A
- CRVS $12.63
- AVG Volume (30 Days)
- ESSA 15.6K
- CRVS 697.0K
- Earning Date
- ESSA 04-23-2025
- CRVS 03-25-2025
- Dividend Yield
- ESSA 3.20%
- CRVS N/A
- EPS Growth
- ESSA N/A
- CRVS N/A
- EPS
- ESSA 1.74
- CRVS N/A
- Revenue
- ESSA $67,430,000.00
- CRVS N/A
- Revenue This Year
- ESSA $9.38
- CRVS N/A
- Revenue Next Year
- ESSA N/A
- CRVS N/A
- P/E Ratio
- ESSA $10.88
- CRVS N/A
- Revenue Growth
- ESSA N/A
- CRVS N/A
- 52 Week Low
- ESSA $15.29
- CRVS $1.30
- 52 Week High
- ESSA $22.22
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ESSA 39.23
- CRVS 28.07
- Support Level
- ESSA $18.93
- CRVS $3.20
- Resistance Level
- ESSA $19.38
- CRVS $3.45
- Average True Range (ATR)
- ESSA 0.30
- CRVS 0.38
- MACD
- ESSA 0.02
- CRVS -0.11
- Stochastic Oscillator
- ESSA 16.36
- CRVS 5.36
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).